For Immediate Release

DIMERIX 2023 GENERAL MEETING RESULTS

MELBOURNE, Australia, 20 June 2023: Dimerix Limited (ASX: DXB) ("Dimerix" or the "Company"), a biopharmaceutical company with a Phase 3 clinical study in inflammatory disease, is pleased to announce the following results from the General Meeting held on 20 June 2023.

All Resolutions considered at the General Meeting were passed by the requisite majorities.

RESOLUTIONS DECIDED BY POLL:

Resolution 1 (Ordinary): Ratification of Convertible Securities
Resolution 2 (Ordinary): Ratification of Shares
Resolution 3 (Ordinary): Approval for issue of Convertible Securities
Resolution 4 (Ordinary): Approval of Issue of Options
Resolution 5A (Ordinary): Approval of Issue of Options
Resolution 5B (Ordinary): Ratification of Options
Resolution 6 (Ordinary): Approval of Issue of Securities
Resolution 7A (Ordinary): Approval of Issue of Options
Resolution 7B (Ordinary): Approval of Issue of Options
Resolution 7C (Ordinary): Approval of Issue of Options
Resolution 7D (Ordinary): Approval of Issue of Options

Details of the voting results by poll and the proxies received in respect of each resolution are attached.

The securities approved by shareholders at the General Meeting will be offered under a prospectus which is expected to be lodged with ASIC and released to ASX on or about 26 June 2023, with the securities expected to be issued on or about 28 June 2023 (subject to change).

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Follow us on LinkedIn and Twitter

Authorised for lodgement by the Board of the Company

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease, and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042.

In 2020, Dimerix completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease, following a successful Phase 2a trial in patients with a range of chronic kidney diseases in 2017. No significant adverse safety events were reported in any trial, and all studies resulted in encouraging data that could provide meaningful clinical outcomes for patients with kidney disease. DMX-200 is also under investigation as a potential treatment for acute respiratory distress syndrome (ARDS) in patients with COVID-19.

FSGS

FSGS is a rare disease that attacks the kidney's filtering units, where blood is cleaned (called the 'glomeruli'), causing irreversible scarring. This leads to permanent kidney damage and eventual end-stage failure of the organ, requiring dialysis or transplantation. For those diagnosed with FSGS the prognosis is not good. The average time from a diagnosis of FSGS to the onset of complete kidney failure is only five years and it affects both adults and children as young as two years old.[1] For those who are fortunate enough to receive a kidney transplant, approximately 60% will get re-occurring FSGS in the transplanted kidney.[2] At this time, there are no drugs specifically approved for FSGS anywhere in the world, so the treatment options and prognosis are poor.

The total global FSGS market was valued at US$12.6 billion in 2022,[3] with a CAGR of 8.2%, driven by approximately 220,000 FSGS sufferers across the 7 major markets[4] and premium orphan drug pricing[5]. Because there is no effective treatment, Dimerix has received Orphan Drug Designation for DMX-200 in both the US and Europe for FSGS.[6] Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and a fast-tracked regulatory pathway to approval. Dimerix reported positive Phase 2a data in FSGS patients in July 2020.[7]

References

1 *Guruswamy Sangameswaran KD, Baradhi KM. (2021) Focal Segmental Glomerulosclerosis), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/*

2 *Front. Immunol., (July 2019) | https://doi.org/10.3389/fimmu.2019.01669*

3 *DataBridge Market Research (2022) Global Focal Segmental Glomerulosclerosis Drugs Market – Industry Trends and Forecast to 2030; https://www.databridgemarketresearch.com/reports/global-focal-segmental-glomerulosclerosis-drugs-market*

4 *Delve Insight Market Research Report (2022): Focal segmental glomerulosclerosis (FSGS) – Market Insight, Epidemiology and market forecast – 2032; https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market*

5 *IQVIA Report (2018), Orphan Drugs in the United States: Growth Trends in Rare Disease Treatments*

6 *ASX release 14Dec2015 and ASX release 21Nov2018*

7 *ASX release 29Jul2020*

Disclosure of Proxy Votes

Dimerix Limited

General Meeting

Tuesday, 20 June 2023

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)		
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**
1 RATIFICATION OF CONVERTIBLE SECURITIES	P	118,448,972	104,742,135 88.43%	12,977,213 10.96%	82,558	729,624 0.62%	105,487,569 89.05%	12,977,213 10.95%	82,558
2 RATIFICATION OF SHARES	P	118,468,863	104,912,026 88.56%	12,977,213 10.95%	62,667	579,624 0.49%	105,507,460 89.05%	12,977,213 10.95%	62,667
3 APPROVAL FOR ISSUE OF CONVERTIBLE SECURITIES	P	118,450,842	104,836,696 88.51%	13,034,522 11.00%	80,688	579,624 0.49%	105,432,130 89.00%	13,034,522 11.00%	80,688
4 APPROVAL OF ISSUE OF OPTIONS	P	118,518,863	104,866,149 88.48%	13,073,090 11.03%	12,667	579,624 0.49%	105,461,583 88.97%	13,073,090 11.03%	12,667
5A APPROVAL OF ISSUE OF OPTIONS	P	109,086,100	95,396,516 87.45%	13,109,960 12.02%	12,667	579,624 0.53%	95,991,950 87.98%	13,109,960 12.02%	12,667
5B RATIFICATION OF OPTIONS	P	95,984,247	82,419,731 85.87%	12,984,892 13.53%	80,688	579,624 0.60%	83,015,165 86.47%	12,984,892 13.53%	80,688
6 APPROVAL OF ISSUE OF SECURITIES	P	116,009,887	102,490,800 88.35%	12,939,463 11.15%	67,667	579,624 0.50%	103,086,234 88.85%	12,939,463 11.15%	67,667

			Proxy Votes				Poll Results (if applicable)		
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**
7A APPROVAL OF ISSUE OF OPTIONS	P	53,584,423	39,962,315 74.58%	13,042,484 24.34%	17,667	579,624 1.08%	40,557,749 75.67%	13,042,484 24.33%	17,667
7B APPROVAL OF ISSUE OF OPTIONS	P	118,276,363	104,654,255 88.48%	13,042,484 11.03%	17,667	579,624 0.49%	105,249,689 88.97%	13,042,484 11.03%	17,667
7C APPROVAL OF ISSUE OF OPTIONS	P	118,518,863	104,891,755 88.50%	13,047,484 11.01%	12,667	579,624 0.49%	105,487,189 88.99%	13,047,484 11.01%	12,667
7D APPROVAL OF ISSUE OF OPTIONS	P	116,059,887	102,435,909 88.26%	13,044,354 11.24%	17,667	579,624 0.50%	103,031,343 88.76%	13,044,354 11.24%	17,667